You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,629,899

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,629,899

Title:	Targeted cargo protein combination therapy
Abstract:	The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.
Inventor(s):	Puri; Raj K. (Potomac, MD)
Assignee:	The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:	14/812,681
Patent Claims:	1. A method of inhibiting a cancer cell that overexpresses an IL-4 receptor, comprising: a. contacting said cancer cell with a targeted cargo protein PRX321 comprising a targeting moiety that specifically binds to an IL-4 receptor, and a cargo moiety that inhibits said cancer cell, and b. contacting said cancer cell with an active anti-cancer agent. 2. The method of claim 1, wherein said cancer cell is a cell of a cancer selected from the group consisting of brain cancer, a hematological cancer, Kaposi sarcoma, bladder cancer, renal cell cancer, breast cancer, pancreatic cancer, non-small cell lung cancer, thyroid cancer, squamous cell carcinoma of the head and neck, colon cancer, bile duct carcinoma, ovarian cancer, a cancer of the gastrointestinal system, mesothelioma, rhabdomyosarcoma, and prostate cancer. 3. The method of claim 1, wherein said cancer cell is selected from the group consisting of a malignant astrocytoma cell, a medulloblastoma cell, a meningioma cell, and a glioma cell. 4. The method of claim 1, wherein said active anti-cancer agent is selected from the group consisting of gemcitabine, doxorubicin, FOLFOX (folinic acid, fluorouracil, and oxaliplatin), premetrexed, irinotecan, temozolamide, cisplatin, oxaliplatin, erlotinib, imatinib, cetuximab, bevacizumab, and rituximab, and an antibody or other active agent used to treat cancer.

Details for Patent 9,629,899

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2028-10-14
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2028-10-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2028-10-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2028-10-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.